T1	CHEM 85 94	abatacept
#1	AnnotatorNotes T1	C1619966; abatacept; Amino Acid, Peptide, or Protein · Pharmacologic Substance
T2	DISO 160 201	artritis idiopática juvenil poliarticular
#2	AnnotatorNotes T2	C0409667; Juvenile Chronic Polyarthritis; Disease or Syndrome
T3	DISO 1039 1051	intolerancia
#3	AnnotatorNotes T3	C0277585; Intolerance to drug; Pathologic Function
T4	CHEM 246 333	fármacos antirreumáticos modificadores de enfermedad (FAMEs) biológicos o no biológicos
#4	AnnotatorNotes T4	C4055380; Biologic Disease-Modifying Antirheumatic Drug; Pharmacologic Substance | C4054347; Non-Biologic Disease-Modifying Antirheumatic Drug; Pharmacologic Substance
T6	PROC 355 395	Estudio fase III, multicéntrico, abierto
T7	PROC 402 450	evaluar la farmacocinética, eficacia y seguridad
T8	CHEM 454 463	abatacept
#5	AnnotatorNotes T8	C1619966; abatacept; Amino Acid, Peptide, or Protein · Pharmacologic Substance
T9	DISO 531 572	artritis idiopática juvenil poliarticular
#6	AnnotatorNotes T9	C0409667; Juvenile Chronic Polyarthritis; Disease or Syndrome
T11	CHEM 617 703	fármacos antirreumáticos modificadores de enfermedad (FAME) biológicos o no biológicos
#8	AnnotatorNotes T11	C4055380; Biologic Disease-Modifying Antirheumatic Drug; Pharmacologic Substance | C4054347; Non-Biologic Disease-Modifying Antirheumatic Drug; Pharmacologic Substance
T13	PROC 705 714	Protocolo
#9	AnnotatorNotes T13	C0008971; Clinical Protocols; Therapeutic or Preventive Procedure
T14	DISO 779 820	Artritis Idiopática Juvenil Poliarticular
#10	AnnotatorNotes T14	C0409667; Juvenile Chronic Polyarthritis; Disease or Syndrome
T15	DISO 878 881	AIJ
#11	AnnotatorNotes T15	C3495559; Juvenile arthritis; Disease or Syndrome
T16	DISO 829 833	AIJp
#12	AnnotatorNotes T16	C0409667; Juvenile Chronic Polyarthritis; Disease or Syndrome
T17	CHEM 1086 1111	antagonistas del anti-TNF
T18	CHEM 1157 1165	anti-TNF
#13	AnnotatorNotes T18	C1562242; Anti-tumor necrosis factor alpha drug (product); Pharmacologic Substance · Immunologic Factor (?)
T19	DISO 574 578	AIJp
#14	AnnotatorNotes T19	C0409667; Juvenile Chronic Polyarthritis; Disease or Syndrome
T20	ANAT 1287 1301	articulaciones
#15	AnnotatorNotes T20	C0022417; Joints; Body Space or Junction | C1269611; Entire joint; Body Space or Junction
T21	DISO 1306 1316	enfermedad
#16	AnnotatorNotes T21	C0012634; Disease; Disease or Syndrome
T22	DISO 1350 1370	enfermedad articular
#17	AnnotatorNotes T22	C0022408; Arthropathy; Disease or Syndrome
T23	ANAT 1386 1400	articulaciones
#18	AnnotatorNotes T23	C0022417; Joints; Body Space or Junction | C1269611; Entire joint; Body Space or Junction
T24	ANAT 1415 1429	articulaciones
#19	AnnotatorNotes T24	C0022417; Joints; Body Space or Junction | C1269611; Entire joint; Body Space or Junction
T25	DISO 1415 1452	articulaciones con movilidad limitada
#20	AnnotatorNotes T25	C1857108; Limitation of joint mobility; Finding
T26	DISO 1507 1530	enfermedades reumáticas
#21	AnnotatorNotes T26	C0035435; Rheumatism; Disease or Syndrome
T27	DISO 1533 1582	enfermedades inmunológicas/inflamatorias crónicas
#22	AnnotatorNotes T27	C1290886; Chronic inflammatory disorder; Disease or Syndrome + C1290894; Chronic disease of immune system; Disease or Syndrome
T28	DISO 203 207	AIJp
#23	AnnotatorNotes T28	C0409667; Juvenile Chronic Polyarthritis; Disease or Syndrome
T29	DISO 1596 1603	uveítis
#24	AnnotatorNotes T29	C0042164; Uveitis; Disease or Syndrome
T30	DISO 1612 1625	AIJ sistémica
#25	AnnotatorNotes T30	C1384600; Systemic onset juvenile chronic arthritis; Disease or Syndrome
T31	DISO 1724 1737	Oligoartritis
#26	AnnotatorNotes T31	C0409702; Undifferentiated inflammatory oligoarthritis; Disease or Syndrome
T32	DISO 1750 1753	AIJ
#27	AnnotatorNotes T32	C3495559; Juvenile arthritis; Disease or Syndrome
T33	CHEM 1802 1816	FAME biológico
#28	AnnotatorNotes T33	C4055380; Biologic Disease-Modifying Antirheumatic Drug; Pharmacologic Substance
T34	DISO 1849 1883	artritis relacionada con entesitis
#29	AnnotatorNotes T34	C3495919; Enthesitis-Related Arthritis; Disease or Syndrome
T35	DISO 1907 1910	Aps
#30	AnnotatorNotes T35	C0003872; Arthritis, Psoriatic; Disease or Syndrome
T36	DISO 1886 1905	artritis psoriásica
#31	AnnotatorNotes T36	C0003872; Arthritis, Psoriatic; Disease or Syndrome
T37	DISO 1937 1957	Enfermedad sistémica
#32	AnnotatorNotes T37	C0442893; Systemic disease; Disease or Syndrome
T38	ANAT 1999 2010	articulares
#33	AnnotatorNotes T38	C0022417; Joints; Body Space or Junction | C1269611; Entire joint; Body Space or Junction
T39	DISO 2017 2030	AIJ sistémica
#34	AnnotatorNotes T39	C1384600; Systemic onset juvenile chronic arthritis; Disease or Syndrome
T40	DISO 2060 2073	organomegalia
#35	AnnotatorNotes T40	C4054315; Organomegaly; Finding
T41	DISO 2042 2048	fiebre
#36	AnnotatorNotes T41	C0015967; Fever; Sign or Symptom
T42	DISO 2050 2058	erupción
#37	AnnotatorNotes T42	C0015230; Exanthema; Sign or Symptom | C0302295; Eruptions; Pathologic Function
T43	PROC 2112 2126	aleatorización
#38	AnnotatorNotes T43	C0034656; Randomization; Research Activity
T44	CHEM 2202 2218	FAMEs biológicos
#39	AnnotatorNotes T44	C4055380; Biologic Disease-Modifying Antirheumatic Drug; Pharmacologic Substance
T45	PROC 95 126	administrado por vía subcutánea
T46	PROC 464 495	administrado por vía subcutánea
T47	DISO 935 945	enfermedad
#40	AnnotatorNotes T47	C0012634; Disease; Disease or Syndrome
T48	CHEM 1066 1083	FAME no biológico
#41	AnnotatorNotes T48	C4054347; Non-Biologic Disease-Modifying Antirheumatic Drug; Pharmacologic Substance
T49	ANAT 1361 1370	articular
#42	AnnotatorNotes T49	C0022417; Joints; Body Space or Junction | C1269611; Entire joint; Body Space or Junction
T50	CHEM 1773 1794	antagonistas anti-TNF
T51	CHEM 2170 2191	antagonistas anti-TNF
T52	Date 12 16	2012
T53	PHYS 44 59	Farmacocinética
#43	AnnotatorNotes T53	C0031327; Drug Kinetics; Physiologic Function
T54	Route 112 126	vía subcutánea
#44	AnnotatorNotes T54	C1522438; Subcutaneous Route of Drug Administration; Functional Concept
T55	Route 128 130	SC
T56	LIVB 135 140	niños
#45	AnnotatorNotes T56	C0008059; Child; Age Group
T58	PHYS 413 428	farmacocinética
#46	AnnotatorNotes T58	C0031327; Drug Kinetics; Physiologic Function
T59	Route 481 495	vía subcutánea
#47	AnnotatorNotes T59	C1522438; Subcutaneous Route of Drug Administration; Functional Concept
T60	LIVB 506 511	niños
#48	AnnotatorNotes T60	C0008059; Child; Age Group
T62	LIVB 864 873;883 905	Pacientes masculinos o femeninos
#49	AnnotatorNotes T62	C0030705; Patients; Patient or Disabled Group + C0025266; Male population group; Population Group + C0043210; Woman; Population Group
T63	Duration 1010 1026	al menos 3 meses
T65	LIVB 1120 1129	pacientes
#50	AnnotatorNotes T65	C0030705; Patients; Patient or Disabled Group
T67	LIVB 1238 1247	pacientes
#51	AnnotatorNotes T67	C0030705; Patients; Patient or Disabled Group
T68	Date 1338 1349	actualmente
T69	LIVB 1487 1496	pacientes
#52	AnnotatorNotes T69	C0030705; Patients; Patient or Disabled Group
T70	Duration 1574 1582	crónicas
#53	AnnotatorNotes T70	C0205191; chronic; Temporal Concept
T71	Duration 1690 1697	6 meses
T72	Neg_cue 1823 1832	excluidos
T73	LIVB 1835 1844	Pacientes
#54	AnnotatorNotes T73	C0030705; Patients; Patient or Disabled Group
T75	Duration 2092 2099	6 meses
T76	LIVB 2131 2140	Pacientes
#55	AnnotatorNotes T76	C0030705; Patients; Patient or Disabled Group
T77	LIVB 143 155	adolescentes
#56	AnnotatorNotes T77	C0205653; Adolescent (age group); Age Group
T79	LIVB 514 526	adolescentes
#57	AnnotatorNotes T79	C0205653; Adolescent (age group); Age Group
T82	LIVB 1221 1230	población
#58	AnnotatorNotes T82	C1257890; Population; Population Group
T57	Route 497 501	s.c.
#59	AnnotatorNotes T57	C1522438; Subcutaneous Route of Drug Administration; Functional Concept
T61	Age 911 922	2 - 17 años
T64	ANAT 1546 1559	inmunológicas
#60	AnnotatorNotes T64	C0020962; Immune system; Body System | C1305754; Entire immune system; Body System
T66	DISO 288 298	enfermedad
#61	AnnotatorNotes T66	C0012634; Disease; Disease or Syndrome
T74	DISO 659 669	enfermedad
#62	AnnotatorNotes T74	C0012634; Disease; Disease or Syndrome
T78	Observation 1757 1762	fallo
#63	AnnotatorNotes T78	C0162643; treatment failure; Finding
T80	PROC 1708 1721	reclutamiento
#64	AnnotatorNotes T80	C0242800; Patient Recruitment; Research Activity
T81	Observation 1134 1154	respuesta inadecuada
#65	AnnotatorNotes T81	C0858218; Inappropriate drug response; Finding
T83	Observation 218 238	respuesta inadecuada
#66	AnnotatorNotes T83	C0858218; Inappropriate drug response; Finding
T84	Observation 589 609	respuesta inadecuada
#67	AnnotatorNotes T84	C0858218; Inappropriate drug response; Finding
T85	Observation 966 1000	respuesta terapéutica insuficiente
#68	AnnotatorNotes T85	C0858218; Inappropriate drug response; Finding
T86	Observation 2149 2156	fallado
#69	AnnotatorNotes T86	C0162643; treatment failure; Finding
A1	Population_data T56 Age
A2	Population_data T77 Age
A3	Population_data T60 Age
A4	Population_data T79 Age
A5	Assertion T69 Negated
A6	Assertion T26 Negated
A7	Assertion T27 Negated
A8	Assertion T29 Negated
A9	Assertion T30 Negated
A10	Assertion T31 Negated
A11	Assertion T32 Negated
A12	Status T3 History_of
A13	Status T21 History_of
A14	Assertion T78 Negated
#7	AnnotatorNotes T55	C1522438; Subcutaneous Route of Drug Administration; Functional Concept
#70	AnnotatorNotes T6	C0282461; Phase 3 Clinical Trials; Research Activity + C1096776; Multicenter Study; Research Activity + C1709323; Open Label Study; Research Activity
#71	AnnotatorNotes T68	C0521116; Current (present time); Temporal Concept
#72	AnnotatorNotes T7	C0201734; Pharmacokinetic study; Research Activity + C0511730; Identify product efficacy and safety issues; Health Care Activity
T5	Quantifier_or_Qualifier 323 333	biológicos
A15	Assertion T5 Negated
#73	AnnotatorNotes T5	C0205460; biological; Qualitative Concept
T10	Quantifier_or_Qualifier 307 317	biológicos
#74	AnnotatorNotes T10	C0205460; biological; Qualitative Concept
T12	Neg_cue 320 322	no
R1	Negation Arg1:T12 Arg2:T5	
R2	Negation Arg1:T72 Arg2:T26	
R3	Negation Arg1:T72 Arg2:T27	
R4	Negation Arg1:T72 Arg2:T29	
T87	Quantifier_or_Qualifier 1583 1594	importantes
A16	Assertion T87 Negated
#75	AnnotatorNotes T87	C3898777; Important; Qualitative Concept
R5	Has_Quantifier_or_Qualifier Arg1:T27 Arg2:T87	
T88	Quantifier_or_Qualifier 1604 1610	activa
A17	Assertion T88 Negated
#76	AnnotatorNotes T88	C0679217; Active State; Idea or Concept
R6	Has_Quantifier_or_Qualifier Arg1:T29 Arg2:T88	
T89	Quantifier_or_Qualifier 1657 1664	activas
A18	Assertion T89 Negated
#77	AnnotatorNotes T89	C0679217; Active State; Idea or Concept
R7	Has_Quantifier_or_Qualifier Arg1:T30 Arg2:T89	
R8	Negation Arg1:T72 Arg2:T89	
R9	Negation Arg1:T72 Arg2:T87	
R10	Negation Arg1:T72 Arg2:T88	
T90	Quantifier_or_Qualifier 1738 1749	persistente
A19	Assertion T90 Negated
#78	AnnotatorNotes T90	C0205322; Persistent; Temporal Concept
R11	Has_Quantifier_or_Qualifier Arg1:T31 Arg2:T90	
R12	Negation Arg1:T72 Arg2:T31	
R13	Negation Arg1:T72 Arg2:T90	
R14	Negation Arg1:T72 Arg2:T32	
R15	Negation Arg1:T72 Arg2:T78	
R16	Before Arg1:T50 Arg2:T78	
R17	Before Arg1:T33 Arg2:T78	
R18	Negation Arg1:T72 Arg2:T30	
R19	Has_Route_or_Mode Arg1:T1 Arg2:T54	
R20	Has_Route_or_Mode Arg1:T1 Arg2:T55	
R21	Used_for Arg1:T1 Arg2:T45	
R22	Experiences Arg1:T56 Arg2:T1	
R23	Experiences Arg1:T77 Arg2:T1	
R24	Experiences Arg1:T77 Arg2:T53	
R25	Experiences Arg1:T56 Arg2:T53	
R26	Experiences Arg1:T56 Arg2:T2	
R27	Experiences Arg1:T56 Arg2:T28	
R28	Experiences Arg1:T77 Arg2:T2	
R29	Experiences Arg1:T77 Arg2:T28	
R30	Experiences Arg1:T56 Arg2:T83	
R31	Experiences Arg1:T77 Arg2:T83	
R32	Before Arg1:T4 Arg2:T1	
R33	Overlap Arg1:T83 Arg2:T4	
R34	Has_Quantifier_or_Qualifier Arg1:T4 Arg2:T10	
R35	Has_Quantifier_or_Qualifier Arg1:T4 Arg2:T5	
R36	Experiences Arg1:T56 Arg2:T66	
R37	Experiences Arg1:T77 Arg2:T66	
R38	Experiences Arg1:T56 Arg2:T4	
R39	Experiences Arg1:T77 Arg2:T4	
R40	Has_Route_or_Mode Arg1:T8 Arg2:T59	
R41	Has_Route_or_Mode Arg1:T8 Arg2:T57	
R42	Used_for Arg1:T8 Arg2:T46	
R43	Experiences Arg1:T60 Arg2:T58	
R44	Experiences Arg1:T79 Arg2:T58	
R45	Experiences Arg1:T60 Arg2:T9	
R46	Experiences Arg1:T60 Arg2:T19	
R47	Experiences Arg1:T60 Arg2:T84	
R48	Experiences Arg1:T60 Arg2:T11	
R49	Experiences Arg1:T60 Arg2:T8	
R50	Experiences Arg1:T79 Arg2:T8	
R51	Experiences Arg1:T79 Arg2:T9	
R52	Experiences Arg1:T79 Arg2:T19	
R53	Experiences Arg1:T79 Arg2:T84	
R54	Experiences Arg1:T79 Arg2:T11	
R55	Experiences Arg1:T79 Arg2:T74	
R56	Experiences Arg1:T60 Arg2:T74	
R57	Before Arg1:T11 Arg2:T8	
R58	Overlap Arg1:T84 Arg2:T11	
T91	Quantifier_or_Qualifier 821 827	Activa
R59	Has_Quantifier_or_Qualifier Arg1:T14 Arg2:T91	
R60	Has_Quantifier_or_Qualifier Arg1:T16 Arg2:T91	
#79	AnnotatorNotes T91	C0205177; Active; Qualitative Concept | C0679217; Active State; Idea or Concept
R61	Experiences Arg1:T62 Arg2:T15	
R62	Has_Age Arg1:T62 Arg2:T61	
R63	Experiences Arg1:T62 Arg2:T47	
T92	Quantifier_or_Qualifier 946 952	activa
R64	Has_Quantifier_or_Qualifier Arg1:T47 Arg2:T92	
#80	AnnotatorNotes T92	C0205177; Active; Qualitative Concept | C0679217; Active State; Idea or Concept
R65	Experiences Arg1:T62 Arg2:T85	
R66	Has_Duration_or_Interval Arg1:T85 Arg2:T63	
A20	Status T85 History_of
R67	Experiences Arg1:T62 Arg2:T3	
R68	Causes Arg1:T48 Arg2:T3	
T93	Neg_cue 1071 1073	no
T94	Quantifier_or_Qualifier 1074 1083	biológico
A21	Assertion T94 Negated
R69	Negation Arg1:T93 Arg2:T94	
R70	Has_Quantifier_or_Qualifier Arg1:T48 Arg2:T94	
R71	Causes Arg1:T17 Arg2:T3	
R72	Experiences Arg1:T62 Arg2:T48	
R73	Experiences Arg1:T62 Arg2:T17	
R74	Overlap Arg1:T85 Arg2:T48	
R75	Overlap Arg1:T85 Arg2:T17	
R76	Overlap Arg1:T81 Arg2:T18	
R77	Experiences Arg1:T65 Arg2:T81	
R78	Experiences Arg1:T65 Arg2:T18	
T95	Quantifier_or_Qualifier 1172 1181	biológico
R79	Has_Quantifier_or_Qualifier Arg1:T18 Arg2:T95	
R80	Location_of Arg1:T20 Arg2:T21	
T96	Quantifier_or_Qualifier 1276 1286	al menos 5
R81	Has_Quantifier_or_Qualifier Arg1:T20 Arg2:T96	
R82	Experiences Arg1:T67 Arg2:T21	
T97	Quantifier_or_Qualifier 1317 1323	activa
#81	AnnotatorNotes T97	C0205177; Active; Qualitative Concept | C0679217; Active State; Idea or Concept
R83	Has_Quantifier_or_Qualifier Arg1:T21 Arg2:T97	
R84	Overlap Arg1:T22 Arg2:T68	
R85	Location_of Arg1:T49 Arg2:T22	
T98	Quantifier_or_Qualifier 1371 1377	activa
#82	AnnotatorNotes T98	C0205177; Active; Qualitative Concept | C0679217; Active State; Idea or Concept
R86	Has_Quantifier_or_Qualifier Arg1:T22 Arg2:T98	
R87	Experiences Arg1:T67 Arg2:T22	
T99	Quantifier_or_Qualifier 1401 1408	activas
#83	AnnotatorNotes T99	C0205177; Active; Qualitative Concept | C0679217; Active State; Idea or Concept
T100	Quantifier_or_Qualifier 1382 1385	≥ 2
R88	Has_Quantifier_or_Qualifier Arg1:T23 Arg2:T100	
R89	Location_of Arg1:T23 Arg2:T22	
R90	Has_Quantifier_or_Qualifier Arg1:T23 Arg2:T99	
T101	Quantifier_or_Qualifier 1411 1414	≥ 2
R91	Has_Quantifier_or_Qualifier Arg1:T24 Arg2:T101	
R92	Location_of Arg1:T24 Arg2:T25	
R93	Experiences Arg1:T67 Arg2:T25	
R94	Experiences Arg1:T69 Arg2:T26	
R95	Experiences Arg1:T69 Arg2:T27	
R96	Location_of Arg1:T64 Arg2:T27	
R97	Has_Duration_or_Interval Arg1:T27 Arg2:T70	
R98	Experiences Arg1:T69 Arg2:T29	
R99	Experiences Arg1:T69 Arg2:T30	
R100	Before Arg1:T30 Arg2:T80	
R101	Has_Duration_or_Interval Arg1:T30 Arg2:T71	
R102	Experiences Arg1:T69 Arg2:T31	
R103	Experiences Arg1:T69 Arg2:T32	
R104	Experiences Arg1:T69 Arg2:T78	
R105	Experiences Arg1:T69 Arg2:T50	
R106	Experiences Arg1:T69 Arg2:T33	
T102	Quantifier_or_Qualifier 1765 1772	3 o más
R108	Experiences Arg1:T73 Arg2:T34	
R109	Experiences Arg1:T73 Arg2:T36	
R110	Experiences Arg1:T73 Arg2:T35	
T103	Quantifier_or_Qualifier 1958 1964	activa
#84	AnnotatorNotes T103	C0205177; Active; Qualitative Concept | C0679217; Active State; Idea or Concept
R111	Has_Quantifier_or_Qualifier Arg1:T37 Arg2:T103	
T104	Observation 1977 2010	características extra-articulares
R112	Has_Duration_or_Interval Arg1:T37 Arg2:T75	
R113	Before Arg1:T37 Arg2:T43	
R114	Causes Arg1:T39 Arg2:T104	
R115	Causes Arg1:T39 Arg2:T41	
R116	Causes Arg1:T39 Arg2:T42	
R117	Causes Arg1:T39 Arg2:T40	
R118	Has_Duration_or_Interval Arg1:T104 Arg2:T75	
R119	Before Arg1:T104 Arg2:T43	
R120	Has_Duration_or_Interval Arg1:T39 Arg2:T75	
R121	Before Arg1:T39 Arg2:T43	
R122	Overlap Arg1:T41 Arg2:T75	
R123	Before Arg1:T41 Arg2:T43	
R124	Overlap Arg1:T42 Arg2:T75	
R125	Before Arg1:T42 Arg2:T43	
R126	Overlap Arg1:T40 Arg2:T75	
R127	Before Arg1:T40 Arg2:T43	
R128	Experiences Arg1:T76 Arg2:T86	
R129	Before Arg1:T51 Arg2:T86	
T105	Quantifier_or_Qualifier 2159 2169	más de dos
R131	Before Arg1:T44 Arg2:T86	
R132	Experiences Arg1:T76 Arg2:T51	
R133	Experiences Arg1:T76 Arg2:T44	
#85	AnnotatorNotes T45	C1273555; Subcutaneous administration of treatment; Therapeutic or Preventive Procedure
#86	AnnotatorNotes T46	C1273555; Subcutaneous administration of treatment; Therapeutic or Preventive Procedure
T106	Quantifier_or_Qualifier 1211 1214	30%
R134	Has_Quantifier_or_Qualifier Arg1:T82 Arg2:T106	
R135	Experiences Arg1:T82 Arg2:T18	
R136	Experiences Arg1:T82 Arg2:T81	
R137	Before Arg1:T83 Arg2:T1	
T107	Quantifier_or_Qualifier 580 586	activa
#87	AnnotatorNotes T107	C0679217; Active State; Idea or Concept
R138	Has_Quantifier_or_Qualifier Arg1:T19 Arg2:T107	
R139	Has_Quantifier_or_Qualifier Arg1:T9 Arg2:T107	
T108	Quantifier_or_Qualifier 677 687	biológicos
#88	AnnotatorNotes T108	C0205460; biological; Qualitative Concept
R140	Has_Quantifier_or_Qualifier Arg1:T11 Arg2:T108	
T109	Quantifier_or_Qualifier 693 703	biológicos
A22	Assertion T109 Negated
#89	AnnotatorNotes T109	C0205460; biological; Qualitative Concept
T110	Neg_cue 690 692	no
R141	Negation Arg1:T110 Arg2:T109	
R142	Has_Quantifier_or_Qualifier Arg1:T11 Arg2:T109	
R107	Has_Quantifier_or_Qualifier Arg1:T78 Arg2:T102	
R130	Has_Quantifier_or_Qualifier Arg1:T86 Arg2:T105	
R143	Before Arg1:T21 Arg2:T22	
R144	Overlap Arg1:T22 Arg2:T25	
R145	Before Arg1:T47 Arg2:T85	
R146	Before Arg1:T21 Arg2:T25	
T111	Observation 1630 1656	características sistémicas
R147	Has_Quantifier_or_Qualifier Arg1:T30 Arg2:T111	
R148	Before Arg1:T19 Arg2:T84	
R149	Before Arg1:T9 Arg2:T84	
R150	Before Arg1:T2 Arg2:T83	
R151	Before Arg1:T28 Arg2:T83
#90	AnnotatorNotes T17	C5200702; Tumor Necrosis Factor-a (TNF-a) Antagonists; Pharmacologic Substance
#91	AnnotatorNotes T51	C5200702; Tumor Necrosis Factor-a (TNF-a) Antagonists; Pharmacologic Substance
#92	AnnotatorNotes T50	C5200702; Tumor Necrosis Factor-a (TNF-a) Antagonists; Pharmacologic Substance
R152	Before Arg1:T84 Arg2:T8	
#93	AnnotatorNotes T95	C0205460; biological; Qualitative Concept
A23	Assertion T111 Negated
R153	Negation Arg1:T72 Arg2:T111	
#94	AnnotatorNotes T94	C0205460; biological; Qualitative Concept
A24	Experiencer T56 Patient
A25	Experiencer T77 Patient
A26	Experiencer T60 Patient
A27	Experiencer T79 Patient
A28	Experiencer T62 Patient
A29	Experiencer T65 Patient
A30	Experiencer T82 Patient
A31	Experiencer T67 Patient
A32	Experiencer T69 Patient
A33	Experiencer T73 Patient
A34	Experiencer T76 Patient
